18F-FLT 摄取与新诊断和复发性脑胶质瘤患者肿瘤分级和 Ki-67 免疫组化的相关性。
Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas.
机构信息
Department of Radiology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
出版信息
J Nucl Med. 2012 Dec;53(12):1911-5. doi: 10.2967/jnumed.112.104729. Epub 2012 Oct 18.
UNLABELLED
We evaluated 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake in patients with newly diagnosed and recurrent gliomas and correlated the results with tumor grade and proliferative activity.
METHODS
(18)F-FLT PET was investigated retrospectively in 56 patients, including 36 with newly diagnosed gliomas and 20 with recurrent gliomas. The standardized uptake values for tumor and normal contralateral hemisphere were calculated, and the tumor-to-normal (T/N) ratio was determined. Tumor grading and proliferative activity were estimated in tissue specimens.
RESULTS
There was a significant difference in T/N ratio among different grades of newly diagnosed gliomas and between low- and high-grade newly diagnosed and recurrent gliomas. (18)F-FLT uptake correlated more strongly with the proliferative activity in newly diagnosed gliomas than in recurrent gliomas.
CONCLUSION
(18)F-FLT PET seems to be useful in the noninvasive assessment of grade and proliferation in gliomas, especially newly diagnosed gliomas.
目的
我们评估了新诊断和复发性脑胶质瘤患者 3'-去氧-3'-(18)F-氟代胸苷（(18)F-FLT）摄取，并将结果与肿瘤分级和增殖活性相关联。
方法
回顾性研究了 56 例患者的 (18)F-FLT PET，其中包括 36 例新诊断的脑胶质瘤患者和 20 例复发性脑胶质瘤患者。计算了肿瘤和对侧正常半球的标准化摄取值，并确定了肿瘤与正常的比值（T/N）。在组织标本中评估了肿瘤分级和增殖活性。
结果
新诊断脑胶质瘤的不同分级之间以及低级别和高级别新诊断和复发性脑胶质瘤之间的 T/N 比值存在显著差异。(18)F-FLT 摄取与新诊断脑胶质瘤的增殖活性相关性强于复发性脑胶质瘤。
结论
(18)F-FLT PET 似乎可用于评估脑胶质瘤的分级和增殖，特别是新诊断的脑胶质瘤，是一种非侵入性的方法。
Zotero 插件